HomeLatest NewsCovid-19FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

FDA authorizes Remdesivir for Certain Non-Hospitalized Patients, New At-Home Test for COVID-19

The Food and Drug Administration Friday expanded the approved uses for Vekury (remdesivir) to include non-hospitalized patients aged 12 and older who test positive for SARS-CoV-2, weigh at least 88 pounds and are at high risk of progressing to severe COVID-19. The agency also authorized emergency use of the drug for high-risk, non-hospitalized pediatric patients who weigh less than 88 but more than 8 pounds, including patients under age 12. The drug previously was limited to hospitalized patients. The expanded uses are based on results from a clinical trial that showed the drug reduced hospitalizations in high-risk, non-hospitalized patients. For more information, see the updated provider and patient fact sheets.

Last week the FDA issued an emergency use authorization for another over-the-counter COVID-19 test, MaximBio ClearDetect COVID-19 Antigen Home Test, that delivers results in 15 minutes.

Stay Connected

Unified Voice Newsletter

Events This Month


04apr9:00 am4:00 pm2023 Spotlight on SD Assisted Living Centers

04apr12:00 pm1:00 pmKeeping Your Cool When It Gets Heated: Diffusing Difficult InteractionsSDAHO Webinar

05apr10:00 am11:00 amHow You Help Save Lives: Organ, Eye and Tissue DonationSDAHO Webinar

06apr1:00 pm2:00 pmSDAHO's Post-Legislative Session Review (Members Only)SDAHO Webinar

06apr3:00 pm4:00 pmDay Drinking - Staying HydratedSDAHO Webinar

By submitting this form, you are consenting to receive marketing emails from: SDAHO, 3708 W Brooks Place, Sioux Falls, SD, 57106, http://sdaho.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact